Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas

Mrinal M. Gounder, Todd M. Bauer, Gary K. Schwartz, P. LoRusso, Parveen Kumar, Kazuki Kato, Bei Tao, Young‐Rock Hong, Pratik Patel, D. Hong